Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 195

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders

Tarnopolsky, Mark A., Beal, M. Flint·2001·Annals of Neurology
DOI 10.1002/ana.1028
Open this paper in CoChat — free account

Abstract

Substantial evidence indicates that bioenergetic dysfunction plays either a primary or secondary role in the pathophysiology of cell death in neurodegenerative and neuromuscular disorders, and even in normal aging. Agents that ameliorate bioenergetic defects may therefore be useful in therapy. Creatine, which increases muscle and brain phosphocreatine concentrations, and may inhibit the activation of the mitochondrial permeability transition, protects against neuronal degeneration in transgenic murine models of amyotrophic lateral sclerosis and Huntington's disease and in chemically mediated neurotoxicity. Initial studies of creatine use in humans appear promising; however, further long‐term, well‐designed trials are needed. Coenzyme Q 10 , Gingko biloba , nicotinamide, riboflavin, carnitine, lipoic acid, and dichloroacetate are other agents which may have beneficial effects on energy metabolism, but the preclinical and clinical evidence for efficacy in neurological diseases remains limited. These compounds are widely used as dietary supplements; however, they must be subjected to rigorous evaluation through randomized, double‐blinded trials to establish efficacy, cost‐effectiveness and safety in neurological disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.1028

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 165

  1. 10.1111/j.1750-3639.1999.tb00216.x · DOI · Paper page
  2. 10.1016/S0959-4388(96)80100-0 · DOI · Paper page
  3. 10.1016/S0025-7125(05)70117-6 · DOI
  4. 10.1046/j.1471-4159.1998.71031321.x · DOI
  5. 10.1023/A:1006881113149 · DOI
  6. 10.1146/annurev.med.50.1.111 · DOI
  7. 10.1006/exnr.1997.6599 · DOI
  8. 10.1016/S0092-8674(00)80186-5 · DOI · Paper page
  9. 10.1126/science.281.5381.1309 · DOI · Paper page
  10. 10.1203/00006450-200011000-00004 · DOI
  11. 10.1056/NEJM199403033300901 · DOI · Paper page
  12. 10.1523/JNEUROSCI.18-01-00156.1998 · DOI · Paper page
  13. 10.1038/6568 · DOI · Paper page
  14. 10.1006/exnr.1999.7049 · DOI · Paper page
  15. 10.1016/S0014-5793(98)01399-4 · DOI
  16. 10.1073/pnas.91.11.5089 · DOI
  17. 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.0.CO;2-6 · DOI
  18. 10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W · DOI
  19. Klopstock T, 1999, Creatine monohydrate in mitochondrial diseases: a double‐blind, placebo‐controlled, cross‐over study in 16 patients with chronic progressive external opthalmolegia or mitochondrial myopathy, Neurology, 52, A543
  20. 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C · DOI · Paper page
  21. 10.1212/WNL.52.4.854 · DOI · Paper page
  22. 10.1001/archneur.57.7.956 · DOI · Paper page
  23. 10.1212/WNL.54.9.1848 · DOI · Paper page
  24. 10.1097/00042752-199810000-00006 · DOI
  25. Guthmiller P, 1994, Cloning and sequencing of rat kidney L‐arginine:glycine amidinotransferase: studies on the mechanism of regulation by growth hormone and creatine, J Biol Chem, 269, 17556, 10.1016/S0021-9258(17)32477-8 · DOI
  26. Stockler S, 1997, Guanidinoacetate methyltransferase deficiency: a newly recognized inborn error of creatine biosynthesis, Wien Klin Wochenschr, 109, 86
  27. 10.1002/1531-8249(200004)47:4<540::AID-ANA23>3.0.CO;2-K · DOI · Paper page
  28. 10.1212/WNL.55.9.1407 · DOI
  29. 10.1016/S0140-6736(96)04116-5 · DOI · Paper page
  30. 10.1006/bbrc.1994.2475 · DOI
  31. 10.1073/pnas.85.3.807 · DOI
  32. 10.1023/A:1006895414925 · DOI
  33. Parise G, 2000, The effect of creatine mtCK and CreaT protein expression following resistance training, Can J Appl Physiol, 25, 396
  34. 10.1002/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I · DOI
  35. 10.1073/pnas.96.20.11492 · DOI · Paper page
  36. 10.1002/ana.410270607 · DOI
  37. 10.1161/01.STR.23.11.1566 · DOI
  38. 10.1016/0165-0327(94)90116-3 · DOI · Paper page
  39. 10.1038/jcbfm.1988.144 · DOI
  40. 10.1152/jappl.1996.80.3.876 · DOI · Paper page
  41. 10.1042/bst0130654 · DOI
  42. 10.1113/jphysiol.1995.sp020525 · DOI
  43. 10.1007/BF01267948 · DOI
  44. Rojo M, 1991, Mitochondrial creatine kinase mediates contact formation between mitochondrial membranes, J Biol Chem, 266, 20290, 10.1016/S0021-9258(18)54921-8 · DOI
  45. 10.1002/biof.5520080311 · DOI
  46. 10.1074/jbc.273.27.16694 · DOI
  47. 10.1016/S0014-5793(97)01045-4 · DOI · Paper page
  48. Klivenyi P, 1998, Neuroprotective effects of creatine in a transgenic animal model of ALS, Nat Med, 5, 347, 10.1038/6568 · DOI · Paper page
  49. 10.1042/0264-6021:3440413 · DOI
  50. 10.1074/jbc.271.23.13435 · DOI
  51. O'Gorman E, 1997, Crystalline mitochondrial inclusion bodies isolated from creatine depleted rat soleus muscle, J Cell Sci, 110, 1403, 10.1242/jcs.110.12.1403 · DOI
  52. Tarnopolsky MA, 2000, Mitochondrial Interest Group Minisymposium (Mitochondria: Interaction of Two Genomes), 27
  53. 10.1161/01.RES.38.2.115 · DOI
  54. 10.1083/jcb.62.1.145 · DOI
  55. 10.1111/j.1748-1716.1995.tb09854.x · DOI · Paper page
  56. 10.1097/00005768-200002000-00007 · DOI · Paper page
  57. 10.1055/s-2000-8848 · DOI
  58. 10.1042/bj2810021 · DOI · Paper page
  59. 10.1152/jappl.1999.86.3.840 · DOI
  60. 10.1152/jappl.1996.81.1.232 · DOI · Paper page
  61. Tarnopolsky MA, Creatine transporter (CreaT) and mitochondrial creatine kinase protein content in myopathies: significant reduction of CreaT in myopathies, Muscle Nerve
  62. 10.1016/S0008-6363(95)00062-3 · DOI
  63. 10.1097/00005768-199912000-00011 · DOI
  64. 10.1152/ajpendo.1994.266.5.E725 · DOI · Paper page
  65. 10.1097/00005768-199902000-00006 · DOI
  66. 10.1056/NEJM199903113401017 · DOI
  67. 10.1007/s004210050291 · DOI · Paper page
  68. 10.1097/00005768-199908000-00005 · DOI · Paper page
  69. 10.1136/jnnp.68.1.112 · DOI
  70. 10.1093/toxsci/56.2.424 · DOI
  71. 10.1097/00005768-200003000-00024 · DOI · Paper page
  72. 10.1111/j.1748-1716.1995.tb09988.x · DOI
  73. 10.1136/fn.82.3.F224 · DOI
  74. 10.1046/j.1471-4159.1995.64062691.x · DOI
  75. 10.1111/j.1471-4159.1981.tb06337.x · DOI
  76. 10.1016/S0006-8993(00)02038-2 · DOI
  77. 10.1016/S0092-8674(00)81369-0 · DOI · Paper page
  78. 10.1002/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K · DOI
  79. 10.1002/1531-8249(200004)47:4<511::AID-ANA15>3.0.CO;2-N · DOI
  80. 10.1016/0005-2744(80)90194-1 · DOI
  81. 10.1212/WNL.53.2.303 · DOI · Paper page
  82. 10.1046/j.1365-2362.1999.00569.x · DOI
  83. 10.1002/(SICI)1097-4598(199909)22:9<1299::AID-MUS24>3.0.CO;2-4 · DOI · Paper page
  84. Hagenfeldt L, 1994, Creatine treatment in MELAS, Muscle Nerve, 17, 1236
  85. 10.1001/archneur.57.8.1224 · DOI
  86. 10.1139/o92-061 · DOI
  87. 10.1073/pnas.93.15.7534 · DOI
  88. 10.1016/0925-4439(95)00028-3 · DOI · Paper page
  89. 10.1016/S0891-5849(96)00330-9 · DOI
  90. 10.3109/10715769409145637 · DOI
  91. 10.1111/j.1749-6632.1999.tb07920.x · DOI
  92. 10.1111/j.1600-0404.1991.tb03962.x · DOI
  93. 10.1212/WNL.38.6.892 · DOI
  94. 10.1016/0022-510X(89)90112-3 · DOI
  95. 10.1212/WNL.39.3.399 · DOI
  96. 10.1016/S0891-5849(99)00132-X · DOI
  97. 10.1016/S0022-510X(98)00296-2 · DOI
  98. 10.1007/s004150050267 · DOI
  99. 10.1002/1531-8257(199909)14:5<855::AID-MDS1023>3.0.CO;2-9 · DOI
  100. 10.1212/WNL.43.5.884 · DOI
  101. Turunen M, 1999, Blood concentration of coenzyme Q(10) increases in rats when esterified forms are administered, J Nutr, 129, 2113
  102. 10.1093/jn/125.7.1904 · DOI
  103. 10.1016/S0891-5849(98)00330-X · DOI
  104. Beal MF, 1997, Coenzyme Q10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice, Brain Res, 783, 109, 10.1016/S0006-8993(97)01192-X · DOI · Paper page
  105. 10.1016/S0140-6736(99)01341-0 · DOI · Paper page
  106. 10.1016/S0022-510X(96)00311-5 · DOI
  107. Sram RJ, 1993, Ginkgo biloba extract (EGb 761) as a free‐radical scavenger, 27
  108. 10.1016/S0006-2952(96)00873-8 · DOI
  109. 10.1016/0006-8993(95)01440-3 · DOI
  110. 10.1016/S0891-5849(99)00103-3 · DOI
  111. 10.1016/S0891-5849(97)00228-1 · DOI
  112. Ramassamy C, 1992, Effects of Gingko biloba extract (EGb 761) on the central nervous system, 27
  113. Ferrante RJ, Effects of Gingko biloba extract on the central nervous system
  114. Le Bars PL, 1997, A placebo‐controlled, double‐blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group, JAMA, 278, 1327, 10.1001/jama.1997.03550160047037 · DOI · Paper page
  115. 10.1001/archneur.55.11.1409 · DOI · Paper page
  116. Eliasson MJL, 1997, Poly(ADP‐ribose) polymerase gene disruption renders mice resistent to cerebral ischemia, Nat Med, 3, 1089, 10.1038/nm1097-1089 · DOI · Paper page
  117. 10.1073/pnas.96.10.5774 · DOI · Paper page
  118. 10.1016/S0304-3940(98)00881-7 · DOI
  119. 10.1016/S0006-8993(98)00829-4 · DOI
  120. 10.1016/0014-4886(95)90033-0 · DOI · Paper page
  121. 10.1016/S0024-3205(96)80008-7 · DOI
  122. 10.1212/WNL.42.11.2147 · DOI
  123. 10.1016/0022-510X(93)90108-B · DOI
  124. 10.1016/S0022-3476(97)70323-8 · DOI
  125. 10.1016/0925-4439(95)00013-T · DOI
  126. 10.1212/WNL.44.11.2153 · DOI
  127. 10.1016/0022-510X(91)90124-P · DOI
  128. 10.1093/brain/122.12.2401 · DOI
  129. 10.1016/0006-291X(85)91334-8 · DOI
  130. 10.1073/pnas.95.16.9562 · DOI · Paper page
  131. 10.1016/0006-8993(90)90255-A · DOI
  132. 10.1016/S1043-6618(05)80044-1 · DOI
  133. 10.1016/0003-9861(90)90019-U · DOI
  134. 10.1016/0006-8993(92)91117-W · DOI
  135. 10.1016/0006-8993(94)90013-2 · DOI
  136. 10.1016/0891-5849(92)90055-L · DOI
  137. 10.1212/WNL.41.11.1726 · DOI
  138. 10.1016/0014-5793(95)01489-6 · DOI
  139. 10.1016/0028-3908(95)00172-7 · DOI
  140. 10.1016/0006-8993(96)00009-1 · DOI
  141. 10.1096/fasebj.12.12.1183 · DOI
  142. 10.1096/fasebj.13.2.411 · DOI · Paper page
  143. 10.1016/S0891-5849(99)00155-0 · DOI
  144. 10.1007/BF00873552 · DOI
  145. 10.1055/s-2000-7739 · DOI
  146. Androne L, 2000, In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy, In Vivo, 14, 327
  147. 10.1080/10715769900300721 · DOI · Paper page
  148. 10.1046/j.1464-5491.1999.00190.x · DOI
  149. 10.1212/WNL.51.5.1331 · DOI
  150. 10.1038/jcbfm.1992.140 · DOI
  151. 10.1111/j.1471-4159.1989.tb07262.x · DOI
  152. 10.1016/0304-3940(96)12542-8 · DOI
  153. McVeigh JJ, 1990, Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts, Am J Physiol, 259, H1079
  154. 10.1136/adc.77.6.535 · DOI
  155. 10.1212/WNL.45.6.1193 · DOI
  156. 10.1016/0730-725X(95)02047-W · DOI
  157. 10.1001/archneur.55.6.849 · DOI
  158. 10.1212/WNL.47.2.529 · DOI
  159. 10.1016/S0022-510X(96)00248-1 · DOI
  160. 10.1016/0022-510X(95)00218-8 · DOI
  161. 10.1212/WNL.50.2.531 · DOI
  162. 10.1212/WNL.55.9.1376 · DOI
  163. Haas R, 2000, Mitochondrial Interest Group Minisymposium (Mitochondria: Interaction of Two Genomes), 2
  164. Gansted U, 1999, Dichloroacetate treatment of mitochondrial myopathy patients, Neurology, 52, A544
  165. 10.1016/S0005-2728(98)00114-5 · DOI · Paper page

Cited by

Metadata

Authors
Tarnopolsky, M. A., & Beal, M. F.
Venue
Annals of Neurology
Publisher
Wiley
Published
2001-04-26
Volume
49
Issue
5
Pages
561-574
ISSN
  • 0364-5134
  • 1531-8249
DOI
10.1002/ana.1028
Cited by
195
References
29
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.